ArticleAmerican journal of translational research2025
Botulinum toxin type A injections demonstrate remarkable efficacy in treating hemifacial spasm in elderly patients.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the effectiveness of botulinum toxin type A (BTX-A) injections in elderly patients with hemifacial spasm (HFS).
methodsIn this retrospective study, a total of 120 elderly patients diagnosed with HFS were recruited and divided into two groups: a research group (n=65) receiving multi-point BTX-A injections and a control group (n=55) undergoing conventional treatment. Comparative analyses were conducted to evaluate therapeutic efficacy, duration of efficacy, adverse reactions, Hamilton Anxiety Scale (HAMA) scores, and Hamilton Depression Scale (HAMD) scores between the two groups. Furthermore, factors influencing treatment outcomes in elderly HFS patients were investigated.
resultsThe research group demonstrated significantly higher overall efficacy, prolonged durations of therapeutic efficacy in grades II, III, and IV, a lower incidence of adverse reactions, and more pronounced improvements in HAMA and HAMD scores. Additionally, Cohen grading, HAMA and HAMD scores, and the treatment approach were independently correlated with treatment failure in elderly patients.
conclusionMulti-point BTX-A injections are highly effective in treating HFS in elderly patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.